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Abstract. Recent studies have shown that the multi- 
functional protein calreticulin can localize to the cell 
nucleus and regulate gene transcription via its ability to 
bind a protein motif in the DNA-binding domain of nu- 
clear hormone receptors. A  number of known modula- 
tors of bone cell function, including vitamin D, act 
through this receptor family, suggesting that calreticu- 
lin may regulate their action in bone cells. We have 
used a gain-of-function strategy to examine this puta- 
tive role of calreticulin in MC3T3-E1 osteoblastic cells. 
Purified calreticulin inhibited the binding of the vita- 
min D  receptor to characterized vitamin D  response el- 
ements in gel retardation assays. This inhibition was 
due to direct protein-protein interactions between the 
vitamin D  receptor and calreticulin. Expression of cal- 
reticulin transcripts declined during MC3T3-E1 osteo- 
blastic differentiation. MC3T3-E1 cells were trans- 
fected with calreticulin expression vectors; stably 
transfected cell lines overexpressing recombinant cal- 
reticulin were established and assayed for vitamin 
D-induced gene expression and the capacity to miner- 
alize. Constitutive calreticulin expression inhibited 
basal and vitamin D-induced expression of the osteo- 
calcin gene, whereas osteopontin gene expression was 
unaffected. This pattern mimicked the gene expression 
pattern observed in parental cells before down-regula- 
tion of endogenous calreticulin expression. In long- 
term cultures of parental or vector-transfected cells, 
let,25-dihydroxyvitamin D 3 (1,251OH]2D3) induced a 
two- to threefold stimulation of 45Ca accumulation into 
the matrix layer. Constitutive expression of calreticulin 
inhibited the 1,25(OH)2D3-induced 45Ca accumulation. 
This result correlated with the complete absence of 
mineralization nodules in long-term cultures of calretic- 
ulin-transfected cells. These data suggest that calretic- 
ulin can regulate bone cell function by interacting with 
specific nuclear hormone receptor-mediated pathways. 
~"~ALREXICUIAN2+ was  initially identified as  the  major 
I[  Ca  storage protein in the sarcoplasmic reticulum 
of skeletal muscle (Ostwald and MacLennan, 1974). 
Subsequent work has revealed that the protein can also be 
detected in the endoplasmic reticulum of nonmuscle tissues 
(Fliegel et al.,  1989;  Opas  et al.,  1991). Calreticulin pos- 
sesses many diverse functional domains such as high affin- 
ity, low capacity- and low affinity, high capacity-CaZ+-bind  - 
ing sites, a COOH-terminal KDEL endoplasmic reticulum 
retention signal, and a nuclear localization signal (for re- 
view see Michalak et al., 1992). 
Recent studies have shown that calreticulin can indeed 
be  detected in  the  nucleus  (Opas  et  al.,  1991;  Dedhar, 
1994; Dedhar et al., 1994). Although the precise molecular 
mechanisms  allowing the escape of calreticulin from the 
endoplasmic reticulum and regulating its translocation to 
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the nucleus are currently unknown, two elegant series of 
experiments have elucidated the function of nuclear cal- 
reticulin (Burns et al., 1994; Dedhar et al., 1994). The pro- 
tein recognizes a conserved amino acid motif, KXFFK/RR 
(where X is either G, A, or V), common to the DNA-bind- 
ing domain of all known members of the nuclear hormone 
receptor family (Burns et al.,  1994; Dedhar et al.,  1994). 
These receptors act as ligand-inducible transcriptional reg- 
ulators  (Fuller, 1991).  By interacting with the conserved 
motif located between the DNA-binding zinc fingers (for 
review see Glass, 1994) of the nuclear receptors, calreticu- 
lin inhibits their capacity to bind DNA in vitro and to acti- 
vate gene expression in vivo (Burns et al., 1994; Dedhar et 
al., 1994). The ability of calreticulin to inhibit nuclear hor- 
mone receptor activity has been directly demonstrated for 
the glucocorticoid (Burns et al., 1994), the androgen (Ded- 
har et al., 1994), and the retinoic acid receptors (Dedhar et 
al., 1994). The functional importance of this inhibition has 
been demonstrated by the observation that calreticulin over- 
expression can influence the retinoic acid-dependent dif- 
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(Dedhar et al.,  1994).  Interestingly, a similar KLGFFKR 
amino acid motif is also found in the cytoplasmic domains 
of all integrin tx subunits (Rojiani et al., 1991), and calretic- 
ulin  has  also  been  shown  to  interact  with  a-integrins 
through  this  sequence  (Leung-Hagesteijn  et  al.,  1994). 
These results suggest the existence of a calreticulin-depen- 
dent signal transduction pathway linking the binding of ex- 
tracellular matrix components by the  integrin  family of 
cell-surface receptors to the coordinate regulation of gene 
expression in the nucleus (Dedhar, 1994). 
The active form of vitamin D, la,25-dihydroxyvitamin 
D 3  (l,25-[OH]2D3,1  also  named  calcitriol),  is  a  known 
modulator of bone cell growth and function (for review 
see Narbaitz, 1992). Vitamin D mainly exerts its pleiotro- 
pic effects after binding to its specific receptor, which is it- 
self a member of the steroid hormone receptor superfam- 
ily (Fuller, 1991).  The ligand-bound vitamin D  receptor 
(VDR) then interacts with its cognate-binding site, termed 
vitamin D  response element (VDRE), to affect the tran- 
scription of target genes (for review see Ozono et al., 1991). 
In osteoblastic cells, vitamin D can stimulate the activity of 
alkaline phosphatase  (Kurihara et al., 1986), and the ex- 
pression of type I collagen (Kurihara et al.,  1986), osteo- 
calcin (Yoon et al., 1988; Demay et al., 1989), and osteopon- 
tin  (Noda  et  al.,  1990).  Functional  VDREs  have  been 
identified and characterized for the promoters of the os- 
teocalcin (Kerner et al.,  1989; Demay et al., 1990) and os- 
teopontin (Noda et al., 1990) genes. 
In addition to the binding of the VDR to certain VDREs 
as a homodimer (Carlberg et al., 1993), the VDR can form 
heterodimers with retinoid X receptors (RXRs) (Yu et al., 
1991; Kliewer et al.,  1992). The RXRs are a family of nu- 
clear  receptors  binding  the  retinoid  9-cis retinoic  acid 
(Heyman et al., 1992; Levin et al., 1992; Mangelsdorf et al., 
1992).  Both the  VDR  and  RXRs  possess the conserved 
KGFFK/RR amino acid motif within their respective zinc 
finger DNA-binding domains (Dedhar et al.,  1994; Burns 
et  al.,  1994),  suggesting  that  VDR-mediated  transcrip- 
tional activation in bone cells may be inhibited by calretic- 
ulin and thus that calreticulin may be involved in the regu- 
lation of osteoblastic differentiation and function. 
We have used the osteoblastic MC3T3-E1 cell line (Sudo 
et al., 1983) to investigate this putative regulatory function 
of calreticulin. We report that purified calreticulin inhib- 
ited  the  binding  of VDR  homodimers  and  VDR-RXR 
heterodimers to the previously characterized osteopontin 
and  osteocalcin VDREs.  Direct protein-protein interac- 
tions between the VDR and calreticulin were demonstrated. 
The expression of the endogenous calreticulin gene was 
shown to be down-regulated during osteoblastic differenti- 
ation of MC3T3-E1  cells. Constitutive expression of cal- 
reticulin achieved by transfection of MC3T3-E1 cells with 
calreticulin expression vectors inhibited basal and vitamin 
D-induced  stimulation  of osteocalcin  expression.  How- 
ever, the stimulation of the expression of osteopontin by 
vitamin D  was unaffected. Mineralization was also inhib- 
ited in  the  calreticulin-expressing clones,  as  assessed  by 
1. Abbreviations used in this paper: 1,25(OH)2D3, 1ct,25-dihydroxyvitamin 
D3; RXR, retinoid X receptor; VDR, vitamin D receptor; VDRE, vitamin 
D response element. 
the reduction in calcium incorporation into the extracellu- 
lar matrix and the complete absence of mineralization nod- 
ules. These results support a role for calreticulin in the reg- 
ulation of osteogenesis through interaction with specific 
nuclear hormone receptor-mediated pathways. 
Materials and Methods 
Gel Retardation  Assays 
The VDR and RXR-13 cDNAs were kind gifts from Dr. J. W. Pike (Ligand 
Pharmaceuticals, San Diego, CA) and Dr. V. Gigu~re (McGill University, 
Montr6al, Qu6bec), respectively, and were in vitro transcribed and trans- 
lated using the TNT-coupled wheat germ lysate system following the in- 
structions of the manufacturer (Promega Corp., Madison, WI). Purified 
recombinant VDR and RXR-c~ expressed in insect cells using baculovirus 
expression vectors (MacDonald et al., 1991) were generously provided by 
Dr. M. Haussler (University of Arizona, Tucson, AZ). For gel-retardation 
assays, 5 I~l from the TNT reactions or 40 ng of the baculovirus-expressed 
receptors were incubated with or without purified calreticulin (Rojiani et 
al., 1991) together with 4 x  103 cpm of probe in gel retention mix (10 mM 
Tris-HC1, pH 7.3, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 2 mM MgCle, 
0.2% NP-40, 12% glycerol, 1.3 mg/ml BSA, 10 -7 M 1,25-[OH]2D3)  in a fi- 
nal vol of 25 I~1. Nonspecific competitor DNA consisted of 8 Ixg poly (dI- 
dC) and 0.2 Ixg salmon sperm DNA or 500 ng of poly (dI-dC) for the in 
vitro-translated  and baculovirus-expressed receptors,  respectively.  The 
receptor and calreticulin proteins were preincubated for 30 min on ice be- 
fore addition of the probe DNA. The probes used were synthetic oligonu- 
cleotides corresponding to the murine osteopontin VDRE  (Noda et al., 
1990)  or the murine osteocalcin VDRE  (Rahman et  al.,  1993).  Probes 
were labeled by Klenow fill-in or kinasing (St-Arnaud and Moir,  1993). 
After incubation for 20 min at room temperature, bound probe was sepa- 
rated from free oligonucleotide on a  7%  30:1  acrylamidePoisacrylamide 
nondenaturing gel in lx  TBE (89 mM Tris-borate [pH 8.3],  2 mM Na  2 
EDTA). Samples were migrated at 150 V  for 3 h  with recirculating lx 
TBE. Gels were then dried and autoradiographed. 
Immunoprecipitation 
The VDR was labeled  with  [35S]methionine using the in vitro  express 
translation kit as instructed by the manufacturer (Stratagene  Corp., La 
Jolla, CA). The labeled receptor was incubated for 60 min on ice with or 
without purified calreticulin (Rojiani et al., 1991) in RIPA buffer (10 mM 
Tris-HC1, pH 8.0, 150 mM NaCI, 1% Triton X-100, 1% sodium deoxycho- 
late) before addition of 10-30 ixl of anti-calreticulin antibody (Lieu et al., 
1988).  To  ascertain  that  VDR  and  calreticulin  interacted  through  the 
KXFFK/RR motif, an additional immunoprecipitation reaction included 
100 ixg of the synthetic peptide KLGFFKR (Dedhar et al., 1994).  Immu- 
noprecipitation reactions were incubated for 4 d at 4°C and antigen-anti- 
body complexes were collected by the addition of protein A-Sepharose 
(Pharmacia Canada, Baie d'Urf6, Qu6bec). The immunocomplexes were 
washed four times in RIPA buffer before analysis by SDS-PAGE on a 
7.5% gel. The fixed, dried gel was subsequently autoradiographed. 
Cells and Tissue Culture Conditions 
The MC3T3-E1  cells were  maintained as previously described (Cande- 
liere et al., 1991).  Mineralization was accelerated by supplementing the 
medium with 10% FBS, 50 ~g/ml ascorbic acid, and 5 mM 13-glycerophos- 
phate (Ecarot-Charrier et al., 1983).  Cultures were stained for mineraliza- 
tion nodules using the yon Kossa method (Mallory, 1942). 
RNA Extraction  and Analysis 
Cells were cultured for 14 d in medium supplemented for mineralization 
and then treated with 10  8 M 1,25-(OH)2D3 in ethanol or vehicle alone for 
24 h. Total RNA was isolated by the lithium chloride-urea technique of 
Auffray and Rougeon (1980). Northern blot hybridization was performed 
as described elsewhere (St-Arnaud et al., 1988). The probes used included 
the 1.9-kb SacI fragment from the human calreticulin cDNA (McCauliffe 
et al., 1992);  a 470-bp EcoRI-PstI fragment from the murine osteocalcin 
cDNA (Celeste et al., 1986);  the full-length murine osteopontin cDNA 
(Smith and Denhardt, 1987); and the MAT1.1 probe for mouse a-tubulin 
(Lemishka et al., 1981). 
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The SV-40 promoter-driven pECE-Cal expression vector was constructed 
by subcloning the 1.9-kb HindIII-calreticulin cDNA fragment from Cal-2 
(Dedhar et al., 1994) into the corresponding site of the pECE vector (Ellis 
et al., 1986) in the sense orientation. 20 ~g of pECE-Cal together with 0.3 
~.g of the pGEM7(KJ1)R selection plasmid (Rudnicki et al., 1992)  were 
transfected into MC3T3-E1 cells by electroporation (2 ×  106 cells; 300 V; 
1000 ixF; 0.2 cm electrode gap). To establish control clones, MC3T3-E1 
cells  were  transfected  with  2  Ixg of pGEM7(KJ1)R  selection  plasmid 
alone. After electroporation, the cells were plated in 100-mm-diam dishes. 
Selection was initiated the next day by adding 1.2 mg/ml G-418 (Canadian 
Life Technologies, Burlington, Ontario)  to  the culture  medium. Three 
control clones and four clones transfected with pECE-Cal were picked 
and established. The clones were maintained as the parental MC3T3-E1 
cells except that the culture medium included 200 txg/ml of G-418. Expres- 
sion of the recombinant calreticulin protein in transfected clones was as- 
sessed by Western blotting of whole-cell extracts with an anti-calreticulin 
antibody (Rokeach et al., 1991)  as previously described (Dedhar et al., 
1994). 
Assay of 45Ca Accumulation 
Accumulation of 45Ca into the matrix layer was measured as described by 
Matsumoto et al. (1991). Cells were cultured for 14 d before treatment 
with 10 8  M 1,25-(OH)2Ds or vehicle for 2 d. 
Results 
Calreticulin Inhibition of DNA Binding by VDR 
We used gel retardation assays with in vitro-translated or 
baculovirus-expressed VDR and RXR proteins to deter- 
mine the effect of purified calreticulin  on the binding of 
VDR homodimers and VDR/RXR heterodimers to char- 
acterized VDREs.  Fig.  1 A  shows that calreticulin inhib- 
ited  the  binding  of the  heterodimer  to  the  murine  os- 
teopontin VDRE (Noda et al., 1990)  in a dose-dependent 
manner (lanes 8-11). A  similar result was obtained using 
the VDRE from the promoter region of the murine osteo- 
calcin gene (Rahman et al., 1993) (Fig. 1 B, lanes 3~5). The 
amount of calreticulin required for the inhibition of VDR 
binding to each VDRE was not significantly different. The 
inhibition by calreticulin was also observed with VDR ho- 
modimers (Fig. 1 A, lanes 4-7), demonstrating that calre- 
ticulin can interact with the VDR protein, and that the in- 
hibition of DNA binding was not mediated solely through 
interaction of calreticulin with RXR. Unprogrammed wheat 
germ lysate (Fig. 1 A, lane 2) or purified calreticulin alone 
(Fig. 1 A, lane 3 and B, lane 2) did not bind to the VDRE 
probes. 
Recent results have suggested that calreticulin interacts 
directly with  nuclear  hormone  receptors  through  a  con- 
served  KXFFK/RR  amino  acid  motif nested  within  the 
DNA-binding domain of the receptor proteins (Dedhar et 
al., 1994; Burns et al., 1994). We addressed the VDR-cal- 
reticulin  interaction using immunoprecipitation reactions 
with labeled VDR, purified calreticulin, and anti-calreticu- 
lin antibodies. Antibodies directed against calreticulin did 
not immunoprecipitate the in vitro-labeled VDR  (Fig.  1 
C, lane 1). However, when purified unlabeled calreticulin 
was added to the reaction, the labeled VDR protein was 
coimmunoprecipitated by the  anti-calreticulin  antibodies 
(Fig. 1 C, lane 2). This result demonstrates a direct interac- 
tion  between  VDR  and  calreticulin.  This  reaction  was 
mediated through the KGFFRR motif of the VDR, as a 
synthetic KLGFFKR peptide  added  simultaneously with 
calreticulin competed for the interaction of the VDR with 
calreticulin and substantially decreased the amount of coim- 
munoprecipitated labeled receptor (Fig. 1 C, lane 3). 
Calreticulin Expression during 
Osteoblastic Differentiation 
MC3T3-E1 cells exhibit a preosteoblastic phenotype dur- 
ing exponential growth. On reaching confluency, the cells 
begin to express osteoblastic phenotype markers such as 
alkaline  phosphatase  and  type  I  collagen  (Sudo  et  al., 
1983).  Long-term cultures  form multilayers of cells  that 
express late osteoblastic differentiation markers and form 
calcified bone tissue  (nodules  of mineralization)  in vitro 
(Sudo et al.,  1983).  This pattern closely recapitulates the 
osteoblastic  differentiation  sequence  (Stein  et  al.,  1990; 
Zhou et al., 1994). 
We extracted  RNA from subconfluent,  confluent,  and 
mineralizing cultures of MC3T3-E1 cells to analyze the ex- 
pression  of  the  endogenous  calreticulin  gene.  Fig.  2  B 
shows  that  the  1.9-kb  calreticulin  mRNA  could  be  de- 
tected in early and confluent cultures  (lanes 1  and 2, re- 
spectively). No calreticulin expression could be detected in 
mineralizing cultures (Fig. 2 B, lane 3). Fig. 2 A shows that 
comparable amounts  of total RNA were loaded  in each 
lane. This pattern of expression of the endogenous calre- 
ticulin gene was observed in two independent experiments 
(data not shown). 
We also probed the RNA blot for expression of osteo- 
blastic phenotype  markers.  Fig.  2  C  shows  that  the  os- 
teopontin gene was expressed at all stages of culture. Thus 
osteopontin expression could be detected in cultures that 
did  or did  not  express the  endogenous  calreticulin  gene 
(compare Fig. 2, B and C). On the contrary, the osteocal- 
cin mRNA was only detected in mineralizing cultures (Fig. 
2 D). Thus osteocalcin gene expression appeared to coin- 
cide  with  the  inhibition  of endogenous  calreticulin  gene 
expression in the cultured cells (Fig. 2, B and D, lane 3). 
Expression of Recombinant Calreticulin 
We isolated four clones stably transfected with the pECE- 
Cal vector (clones SV-Cal 4, SV-Cal 5, SV-Cal 6, and SV- 
Cal 12). Three clones transfected with the selection vector 
alone served as controls. 
Fig. 3 shows the relative expression levels for the calre- 
ticulin protein in parental MC3T3-E1 cells and the control 
and  transfected  clones.  Elevated  calreticulin  protein  ex- 
pression was achieved in all four clones transfected with 
the calreticulin expression vector. The increase in calretic- 
ulin  expression was estimated to vary between two- and 
fivefold over parental levels. The expression of the recom- 
binant  calreticulin  protein  was  constitutive  and  main- 
tained in long-term cultures of the transfected clones (data 
not shown).  In both parental MC3T3-E1  cells and trans- 
fected clones, calreticulin was detected in the nucleus and 
the  perinuclear  region  using  immunocytochemistry (not 
shown),  as  demonstrated  for  other  cell  types  (Dedhar, 
1994);  the relative abundance  of nuclear calreticulin was 
increased in the clones transfected with the calreticulin ex- 
pression vector (data not shown). 
Enhanced calreticulin expression affected the morphology 
of the cells. This change was more evident in early cultures 
St-Arnaud et al. Calreticulin Inhibits Mineralization  1353 Figure 1.  Calreticulin interacts with the VDR protein to inhibit the binding of VDR homodimers and VDR-RXR heterodimers to char- 
acterized VDREs. (A) VDR and RXR-13 were in vitro translated and incubated with a labeled oligonucleotide corresponding to the mu- 
rine osteopontin VDRE in the presence or absence of purified calreticulin (10 ng/p-1). Probe, unprogrammed lysate,  and calreticulin 
alone were migrated as controls in lanes 1, 2, and 3, respectively.  (B) Baculovirus-expressed VDR and RXR-a were incubated with a 
murine osteocalcin VDRE oligonucleotide probe. Increasing amounts of purified calreticulin (10 ng/p-1) were added as indicated above 
lanes 4-6. Probe and calreticulin  were migrated in lanes I and 2. The binding reactions were analyzed using the gel retardation assay on 
a 7% nondenaturing gel. (C) SDS-PAGE analysis  of immunoprecipitation reactions. 35S-labeled VDR was incubated with or without 
purified calreticulin  and an anti-calreticulin  antibody. In the presence of calreticulin,  the labeled receptor was associated with the immu- 
nocomplexes (lanes 2 and 3). Addition of a synthetic peptide (KLGFFKR; 100 p.g) substantially reduced the amount of immunoprecip- 
itated receptor (lane 3). 
that had just reached confluency. The clones overexpress- 
ing calreticulin had a spindle-shaped appearance compared 
with  the  characteristic  cuboidal  osteoblastic  morphology 
of the parental  cells  and the control clones (Fig.  4).  This 
morphological change became less apparent in long-term, 
multilayer cultures (data not shown). 
Calreticulin Overexpression  Selectively Inhibits 
Gene Expression 
Long-term  (14  d)  cultures  of  control  and  calreticulin- 
expressing clones were treated with 1,25-(OH)2D3 for 24 h 
and  total  RNA was extracted  to analyze the influence  of 
calreticulin overexpression on vitamin D-stimulated gene 
expression in bone cells. Fig. 5 shows that constitutive cal- 
reticulin expression inhibited  the induction of osteocalcin 
expression by vitamin D  in all clones studied. Basal levels 
of  osteocalcin  mRNA  were  also  drastically  down-regu- 
lated in calreticulin-expressing  clones  (Fig.  5).  These  ob- 
servations  are  consistent  with  the  pattern  of osteocalcin 
gene  expression  observed in parental  cells,  where  osteo- 
calcin mRNA could not be detected  in subconfluent  and 
confluent cultures  of MC3T3-E1  cells  that  expressed  en- 
dogenous ealreticulin mRNA (Fig. 2). Similarly, vitamin D 
treatment  of subconfluent  and confluent MC3T3-E1  cul- 
tures did not induce osteocalcin gene expression (data not 
shown).  Interestingly,  the vitamin D-induced stimulation 
of the expression of the osteopontin gene was unaffected 
by calreticulin  (Fig.  5).  This  result  is  in  accord  with  the 
data obtained in parental cell cultures, where osteopontin 
expression  could readily be  detected  in  early cultures  of 
MC3T3-E1 cells that expressed significant levels of endog- 
enous calreticulin  mRNA (Fig. 2). Thus our observations 
suggest  that  calreticulin  overexpression  had  specific  ef- 
fects on the modulation of gene expression by nuclear hor- 
mone receptors and did not inhibit gene expression in gen- 
eral.  Indeed,  the  expression  of  a-tubulin,  which  was 
analyzed  to  monitor for equal  loading  of RNA for each 
sample,  was  unaffected  by  calreticulin  overexpression 
(Fig. 5). 
Constitutive  Calreticulin Expression 
Inhibits Mineralization 
Multilayer  cultures  of  MC3T3-E1  cells  deposit  mineral 
and  form  calcified  bone  tissue  after  14-21  d  in  culture 
(Sudo et al.,  1983).  This  osteogenic process can be docu- 
mented by counting the number of mineralization nodules 
and  by  measuring  the  incorporation  of labeled  calcium 
into  the  extracellular  matrix.  The  calcium  accumulation 
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of calreticulin and osteobtast 
phenotype  markers  during 
MC3T3-E1  osteoblastic  dif- 
ferentiation. Total RNA was 
isolated  from  subconfluent 
(day  2),  confluent  (day  4), 
and  mineralizing  (day  21) 
MC3T3-E1  cells  and  ana- 
lyzed by Northern blot assay. 
(A)  Ethidium  bromide- 
stained  ribosomal  RNA 
showing  equivalent  loading 
for  all  samples.  The  RNA 
was transferred onto a nylon 
membrane, cross-linked,  and 
hybridized to specific  probes 
for calreticulin  (B), osteopon- 
tin (C), and osteocalcin (D). 
The  major  1.5-kb  osteopon- 
tin transcript is shown in C. 
into the matrix has been shown to be stimulated  by treat- 
ment of the cultures with 1,25-(OH)2D 3 (Matsumoto et al., 
1991). We have used both assays to analyze the influence 
of constitutive calreticulin expression on mineralization in 
osteoblastic cells. 
Fig.  6 A  shows a  14-d-old culture  of the  control clone 
G7KJ1-2 that was stained for mineralization nodules using 
the  von  Kossa  method  (Mallory,  1942).  Long-term  cul- 
tures of all three control clones yielded similar results that 
were representative  of the mineralization  observed in pa- 
rental MC3T3-E1 cultures (not shown). Fig. 6 B illustrates 
the complete absence of mineralization  nodules observed 
in calreticulin-overexpressing clones. The data from a typ- 
ical mineralization  experiment  is summarized  in Table  I. 
The cultures of the control clone G7KJ1-2 contained 53 +_ 
4  nodules  (mean  _+  SEM,  n  =  4),  whereas  the  cultures 
from  all  the  clones  expressing  calreticulin  constitutively 
contained no nodules (0.6 _+ 0.3; mean +  SEM, n  =  2 for 
each of the four clones). 
Vitamin  D-induced  stimulation  of 45Ca  incorporation 
Figure 3.  Expression of the calreticulin protein in parental cells, 
overexpressing clones, and control clones.  MC3T3-E1 cells were 
electroporated with the pGEM7(KJ1)R selection plasmid alone 
or in combination with the pECE-Cal expression vector for cal- 
reticulin as described in Materials and Methods. G-418-resistant 
clones were picked  and  expanded,  and total-cell extracts  from 
four clones transfected with pECE-Cal and three control clones 
transfected with pGEM7(KJJ)R alone were analyzed for calretic- 
ulin protein expression by Western blot assay. The levels of cal- 
reticulin expressed in untransfected MC3T3-E1 cells is shown for 
comparison purposes in lane 1. 
Figure 4.  Calreticulin overexpression affects the morphology of 
osteoblastic cells at confluence. Phase-contrast photomicrographs 
of the control clone G7KJ-2 (A) and the calreticulin  overexpress- 
ing clone SV-Cal 4 (B) grown to confluence (day 4) in medium 
supplemented for mineralization. Notice the characteristic osteo- 
blastic  cuboidal morphology of the control cells and the spindle- 
shaped, fibroblastic appearance of the cells expressing increased 
levels of recombinant calreticulin. 
into the extracellular matrix was also inhibited in calretic- 
ulin-transfected  clones.  We  observed  the  previously  re- 
ported  twofold stimulation  of calcium incorporation  into 
the matrix by vitamin D  (Matsumoto  et  al.,  1991) in cul- 
tures of MC3T3-E1  cells and in cultures of all three con- 
trol clones (Fig. 7).  Constitutive expression of calreticulin 
inhibited  calcium incorporation in response to vitamin D 
treatment in all four clones (Fig. 7). 
Discussion 
We have shown that constitutive expression of calreticulin 
in osteoblastic cells  inhibited  mineralization.  This  inhibi- 
tion was most likely mediated through specific modulation 
of  gene  expression  by  calreticulin,  as  we  have  demon- 
strated that calreticulin could interact with the vitamin D 
receptor to inhibit its binding to cognate response elements 
in vitro, and selectively inhibit certain vitamin D-mediated 
transcriptional  responses  in  vivo.  Our  results  support  a 
role for calreticulin in the regulation of osteoblastic differ- 
entiation and function. 
The skeleton  is the body's major repository of calcium 
in the form of hydroxyapatite crystals. Mineralization, i.e., 
the deposition of mineral along the fibrils of the collagen 
St-Arnaud et al. Calreticulin Inhibits Mineralization  1355 Figure 5.  Calreticulin overexpression selectively  inhibits  the vita- 
min D-induced stimulation of osteocalcin expression without af- 
fecting vitamin D-stimulated osteopontin expression.  Total RNA 
was isolated from mineralizing (day 14) cultures of one control 
clone  (lanes  1  and 2)  and  the  four calreticulin  overexpressing 
clones (lanes 3-10) treated with (even-numbered lanes) or with- 
out (odd-numbered lanes)  10  -8 M  1,25-(OH)2D 3 for 24 h. The 
RNA was analyzed by Northern blot assay with specific  probes 
for osteocalcin, osteopontin, and a-tubulin (to monitor for varia- 
tions in sample loading). Observed transcript sizes are indicated 
on the  right.  Multiple  transcripts  for murine  osteopontin have 
been described previously (Miyazaki et al., 1990). 
matrix of bone, is under the control of the osteoblast (Ter- 
mine, 1993). But the role of the osteoblast is not to act as a 
calcium-storage compartment since a proportion of the skel- 
etal content of calcium is freely exchangeable with the ex- 
tracellular  fluids  and serves  as the major storage pool of 
calcium (Broadus, 1993). Moreover, the function of the os- 
teoblast is not dependent  on the availability of a  large in- 
tracellular store of calcium, in contrast, for example, to the 
function of skeletal myotubes which require rapid calcium 
release to initiate muscle contraction. Thus it is likely that 
the role of calreticulin in osteoblasts is not limited to a cal- 
cium storage function. 
Indeed,  we  have  shown  that  calreticulin  can  influence 
gene expression and mineralization. The inhibition of min- 
eral deposition cannot be simply explained by the sequestra- 
tion of calcium inside the cells by the recombinant calreticu- 
lin protein. First, the levels of expression that we achieved 
in the transfected clones were not disproportionately high. 
Second, under the conditions used, the extracellular  fluid 
was supersaturated  with regard to calcium and phosphate. 
In experiments  measuring  the  stimulation  of labeled  cal- 
cium into  the  extracellular  matrix  by vitamin  D  (Fig.  7), 
the  calreticulin-expressing  clones  had  similar  baseline 
amounts  of 45Ca incorporated in the matrix  (not shown). 
The  mechanisms  responsible  for the  actual  inhibition  of 
calcium  incorporation  when  the  calreticulin-transfected 
clones were treated with vitamin D  are unclear. Vitamin D 
treatment  had no effect on the expression of the endoge- 
nous  calreticulin  gene  in  MC3T3-E1  cells  (Prud'homme, 
J., and R. St-Arnaud, unpublished observations). 
In addition to vitamin D, a number of steroid hormones 
or morphogens  binding  to  members  of the  nuclear  hor- 
mone receptor superfamily can modulate gene expression 
in osteoblasts. In MC3T3-E1 cells, glucocorticoids have been 
shown to inhibit prostaglandin  E2 synthesis  (Hughes-Ful- 
ford et al., 1992) and increase the expression of betaglycan 
Figure 6.  Constitutive calreticulin  expression inhibits  mineraliza- 
tion.  Long-term (day 14) cultures, supplemented for mineraliza- 
tion,  of control clone  G7KJ1-2  (A)  and  calreticulin-expressing 
clone SV-Cal  12 (B) were stained for mineralization nodules us- 
ing the von Kossa method. The nodules appear as dark spots in 
the bright-field photograph. 
(Nakayama et al., 1994). Estrogen receptors are expressed 
in  osteoblasts  (Eriksen  et  al.,  1988)  and  17-[3 estradiol 
down-regulates the transcriptional activity of the interleu- 
kin-6 gene promoter and inhibits the expression of the gly- 
coprotein 130, a subunit of cytokine receptors (Manolagas, 
S. C. 1995. Bone.  16 [Suppl.  1]:91S.). Retinoic acid stimu- 
lates  the  expression  of alkaline  phosphatase  and  induces 
differentiation of preosteoblastic cell lines (Ng et al., 1988; 
Heath et al., 1989). All of these receptor-mediated responses 
represent  putative  targets  for modulation by calreticulin. 
Our results,  showing that  calreticulin  inhibited  some but 
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Cultures of Control and Calreticulin-transfected Clones 
Clone  Number of nodules  Mean _+ SEM 
G7KJ1-2 (control)  47; 52; 50; 63  53 -  4 
SV-Cal 4  2; 0 
SV-Cal 5  0; 0 
SV-Cal 6  0;  1 
SV-Cal 12  0; 2  0.6 _+ 0.3 
Cells were grown for 14 d in media supplemented for mineralization, then stained us- 
ing the yon Kossa method. Mineralization nodules were counted manually. The con- 
trol clone G7KJ1-2 was grown in quadruplicate, whereas the calreticulin-transfected 
clones were cultured in duplicate dishes. 
not  all  of the  transcriptional  responses  mediated  by the 
VDR,  suggest that  certain of these  nuclear  hormone re- 
ceptor-dependent pathways will be left intact while others 
may be affected. It would be interesting to investigate tran- 
scriptional responses to various steroids in bone cells ex- 
pressing calreticulin constitutively. 
The response to vitamin D was not completely abrogated 
in  clones expressing the  recombinant calreticulin  protein 
(Fig. 5). This could suggest that the VDR was in stochio- 
metric excess over calreticulin in the transfected clones, thus 
allowing the excess of ligand-bound VDR to escape inhibi- 
tion by calreticulin and activate transcription. Indeed, vita- 
min D  treatment has been shown to induce the expression 
of VDR mRNA and protein in bone cells (Mahonen et al., 
1990).  Alternatively, the residual vitamin D  response ob- 
served in  calreticulin-transfected  clones  could  be due  to 
the documented nongenomic effects of vitamin D  (for re- 
view see Norman et al., 1992), which may not be affected 
by constitutive calreticulin expression. 
Our results have demonstrated that calreticulin inhibits 
VDR binding to both the osteopontin and the osteocalcin 
VDRE  (Fig.  1).  However, the  two  genes responded  dis- 
similarly when the calreticulin-expressing clones were chal- 
lenged with vitamin D  (Fig. 5). Despite differences between 
Figure  7.  Calreticulin  overexpression  inhibits  the  vitamin 
D-induced  stimulation of calcium incorporation  into  the extra- 
cellular matrix. 45Ca incorporation in long-term (day 14) cultures 
of parental MC3T3-E1  cells, three control clones and four calre- 
ticulin-expressing clones treated  with  or without  vitamin D  was 
measured  as described  by Matsumoto  et  al.  (1991).  Results are 
expressed as mean fold induction  -4-  SEM  of three independent 
experiments performed in duplicate. 
the sequences of the two VDREs (Kerner et al., 1989; De- 
may et  al.,  1990;  Rahman  et  al.,  1993)  that  could  affect 
VDR binding affinity to each response element (Nishikawa 
et al., 1993), we were unable to detect any difference in the 
capacity of calreticulin  to  inhibit  VDR  binding  to  each 
VDRE. Thus the structure of the response element cannot 
seem  to  account  for  the  variation  in  transcription.  It is 
more likely that the expression of each gene is dictated by 
the structure of the entire promoter region, and not just a 
single element. The pattern observed in the parental cells 
supports  this  view.  Indeed,  the  osteopontin  mRNA  was 
readily detected in early cultures of MC3T3-E1  cells that 
also expressed calreticulin (Fig. 2). On the contrary, osteo- 
calcin transcripts were only observed in long-term cultures 
that  had  down-regulated  calreticulin  expression  (Fig.  2). 
Thus  it appears that  calreticulin  expression inhibits both 
steady-state and stimulated osteocalcin expression, whereas 
it does not affect the transcription of the osteopontin gene. 
In this respect, the pattern of expression of these two os- 
teoblastic phenotype markers that we measured in the cal- 
reticulin-expressing clones closely mimicked what was ob- 
served in the parental MC3T3-E1 cells. 
There was no correlation between the level of calreticu- 
lin overexpression achieved in independent clones and the 
inhibition  of basal  and  stimulated  osteocalcin  transcrip- 
tion, as all clones exhibited an identical blunted osteocal- 
cin response (see Figs. 3 and 5). Our results suggest that it 
was not the magnitude of the expression of the recombi- 
nant protein per se that affected the osteocalcin response, 
but  the  fact  that  calreticulin  expression  was  constitutive 
and therefore not down-regulated in long-term cultures of 
the  transfected  clones.  Again,  this  observation  parallels 
the  pattern of osteocalcin gene expression that we docu- 
mented in nontransfected MC3T3-E1 cultures (Fig. 2). 
Attachment to extracellular matrix components modu- 
lates gene expression and differentiation of bone cells. For 
example, differentiation of canalicular cell processes was 
observed  after  contact  of MC3T3-E1  cells  with  laminin 
(Vukicevic et  al.,  1990),  and  gene  expression  is  affected 
when preosteoblastic cells are plated on various extracel- 
lular matrix components (Traianedes et al., 1993).  Osteo- 
blasts express various forms of the integrin family of cell 
surface receptors for matrix proteins (Hughes et al., 1993; 
Saito et al., 1994), and inhibition of integrin function using 
subunit-specific antibodies has been shown to prevent cy- 
tokine-induced osteoblastic differentiation of osteosarcoma 
cells (Dedhar, 1989).  Calreticulin binds to a-integrin sub- 
units  (Leung-Hagesteijn  et  al.,  1994)  and  recent  results 
suggest that this interaction can modulate the affinity state 
of  integrins  (Dedhar,  1994).  Moreover,  calreticulin  can 
modulate nuclear hormone receptor-dependent  gene ex- 
pression (Dedhar  et al.,  1994;  Burns  et al.,  1994).  Taken 
together, these observations support the existence of a cal- 
reticulin-modulated  signal  transduction  pathway  linking 
substratum attachment via integrin receptors to the  con- 
trol of gene expression. Our results further support an im- 
portant  role  for this  pathway in the  regulation  of osteo- 
blastic differentiation and function. 
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Note Added in Proof.  After completion of this work, a  report was pub- 
lished confirming the inhibition of vitamin D  signal transduction by cal- 
reticulin (Wheeler,  D.  G.,  J.  Horsford,  M.  Michalak, J.  H.  White,  and 
G. N. Hendy. 1995. Nucleic Acids Res. 23:3269-3274). 
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